You are here: Home » Reuters » News
Business Standard

Israel's Teva Pharma appoints Lundbeck's Kare Schultz as CEO

Reuters  |  JERUSALEM 

(Reuters) - Pharmaceutical Industries Ltd named H Lundbeck A/S Chief Executive Kare Schultz as its new and president on Monday, as it struggles with heavy debts and fierce competition for its generic drugs in the United States.

Israel-based Teva's shares, which plunged after the company issued poor second-quarter results last month, rose 8 percent in early trade in Tel Aviv.

Schultz will succeed Yitzhak Peterburg, who will continue as Teva's interim until Schultz takes over.

Schultz had been widely seen as heir apparent at the world's largest diabetes drugmaker Novo Nordisk before stepping down in 2015 when Novo's former said he would stay until 2019.

Schultz was appointed of Denmark's Lundbeck in May 2015 shortly after the respected executive quit Novo and Lundbeck's share price has more than tripled since he took over and returned the company to profit by slimming costs.

is facing accelerating price erosion in the United States and is saddled with more than $32 billion in debt, much of it stemming from financing the purchase of Allergan's generics business. Analysts and investors believe paid too much for Actavis and that led to the resignation of Erez Vigodman in February.

(Reporting by Steven Scheer, Stine Jacobsen, Ben Hirschler and Abinaya Vijayaraghavan)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, September 11 2017. 13:37 IST